ImmuneRegen BioSciences(R) Announces Collaboration With the Department of Tumor Immunology of the Radboud University Nijmegen Me
April 27 2010 - 8:00AM
Marketwired
ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR
Biosciences Holdings Inc. (OTCBB: IRBS), today announced a
collaboration and research agreement with the Department of Tumor
Immunology of the Radboud University Nijmegen Medical Centre
(RUMC), in the Netherlands to commence studies utilizing
ImmuneRegen's Homspera. Under the agreement top cancer vaccine
experts at RUMC will perform exploratory studies on Homspera
relating to its adjuvant and immunomodulatory properties for
potential application in experimental cancer vaccines and
immunotherapy for cancer.
Homspera has been shown to be effective in enhancing the
efficacy of a novel cancer vaccine in an experimental melanoma
model, and previous studies have demonstrated efficacy in enhancing
immune responses to infectious disease vaccines, such as influenza.
The studies to be performed at RUMC are designed to expand on that
research, and further define the mechanisms that make Homspera an
effective vaccine adjuvant.
The research will be directed by Professor Gosse Adema, Chair
and full professor of Molecular Immunology in the Department of
Tumor Immunology, Nijmegen Centre for Molecular Life Science.
Professor Adema is also Theme Leader for Infection, Immunity and
Tissue Repair. Dr. Adema has published over 150 scientific
publications on scientific topics ranging from the role of
dendritic cells in cancer immunology and cancer vaccines to the
identification of cancer specific antigens. Other important RUMC
Department of Tumor Immunology researchers who will participate in
these studies with ImmuneRegen's Homspera include Dr. Jolanda de
Vries and Professor Carl Figdor.
Radboud University Nijmegen Medical Centre is a leading academic
centre with expertise in medical science and healthcare in the
Netherlands. Scientific expertise plays an essential part in their
organization and connects research, education and patient care.
More than 8,000 staff and 2,500 students are committed and
ambitious, helping to shape the future of healthcare and medical
science.
"We are pleased that Professor Adema and his team are interested
in evaluating the impact of Homspera in their cancer vaccine
models, and hope this is the beginning of a long and fruitful
relationship that takes our compound into a number of vaccine
adjuvant, and perhaps other, studies," said Hal Siegel, Ph.D.,
ImmuneRegen's Chief Scientific Officer.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR
BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage
biotechnology company focused on the research, development and
licensing of Homspera®. Homspera is an adult
stem cell active compound that in study results has been shown to
regenerate and strengthen the immune system and enhance wound
healing. Homspera is being developed for potential use against
infectious diseases as a stand-alone or combination therapy.
Additionally, Homspera is being developed for use as a therapeutic
for Idiopathic Pulmonary Fibrosis, an indication which ImmuneRegen
has recently submitted for Orphan Drug Status. To advance its
mission, the Scottsdale, Arizona based company has forged numerous
study partnerships with industry and academic leaders, including
MPI Research, Celgene Cellular Therapeutics, HemoGenix, Lovelace
Respiratory Research Institute and Virion Systems. For more
information, please visit www.immuneregen.com.
Statements about ImmuneRegen's future expectations, including
statements about the potential use and scientific results for
ImmuneRegen's drug candidates, science and technology, and all
other statements in this press release other than historical facts,
are "forward-looking statements" within the meaning of Section 27A
of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private
Securities Litigation Reform Act of 1995. ImmuneRegen intends that
such forward-looking statements be subject to the safe harbors
created thereby. These future events may not occur as and when
expected, if at all, and, together with ImmuneRegen's business, are
subject to various risks and uncertainties. ImmuneRegen's actual
results could differ materially from expected results as a result
of a number of factors, including the uncertainties inherent in
research and development collaborations, pre-clinical and clinical
trials and product development programs (including, but not limited
to the fact that future results or research and development efforts
may prove less encouraging than current results or cause side
effects not observed in current pre-clinical trials), the
evaluation of potential opportunities, the level of corporate
expenditures and monies available for further studies, capital
market conditions, and others set forth in ImmuneRegen's periodic
report on Form 10-Q for the three months ended September 30, 2009
as filed with the Securities and Exchange Commission and report on
Form 10-K for the year ended December 31, 2009 as filed with the
Securities and Exchange Commission. There are no guarantees that
any of ImmuneRegen's proposed products will prove to be
commercially successful. ImmuneRegen undertakes no duty to update
forward-looking statements.
Contact: Michael K. Wilhelm Email: Email Contact John
Fermanis Email: Email Contact ImmuneRegen BioSciences Inc. Phone:
480-922-3926 Investor Contact: Redwood Consultants, LLC
Phone: 415-884-0348
IR BioSciences (CE) (USOTC:IRBS)
Historical Stock Chart
From May 2024 to Jun 2024
IR BioSciences (CE) (USOTC:IRBS)
Historical Stock Chart
From Jun 2023 to Jun 2024